By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
| Currency | US Dollars |
| Share Price | $ 180.44 |
| Change Today | $ -0.86 |
| % Change | -0.47 % |
| 52 Week High | $182.12 |
| 52 Week Low | $118.84 |
| Volume | 1,472,765 |
| Shares Issued | 145.80m |
| Market Cap | $26,308m |
| RiskGrade | 259 |
| Strong Buy | 8 |
| Buy | 6 |
| Neutral | 20 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 34 |

| Time | Volume / Share Price |
| 16:00 | 152,402 @ $180.44 |
| 15:59 | 100 @ $180.45 |
| 15:59 | 100 @ $180.43 |
| 15:59 | 100 @ $180.39 |
| 15:59 | 100 @ $180.37 |
You are here: research